

**AUTHOR RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (COMPREHENSIVE)—COCATS 4 TASK FORCE 15: TRAINING IN CARDIOVASCULAR RESEARCH AND SCHOLARLY ACTIVITY**

<b>Committee Member</b>	<b>Employment</b>	<b>Consultant</b>	<b>Speaker's Bureau</b>	<b>Ownership/ Partnership/ Principal</b>	<b>Personal Research</b>	<b>Institutional/ Organizational or Other Financial Benefit</b>	<b>Expert Witness</b>
Robert A. Harrington (Chair)	Stanford University— Arthur L. Bloomfield Professor of Medicine; Chair, Department of Medicine	<ul style="list-style-type: none"> <li>• Adverse Events†</li> <li>• Baxter BioSurgery</li> <li>• Bristol-Myers Squibb</li> <li>• CLS Behring</li> <li>• Daiichi-Sankyo</li> <li>• Eli Lilly</li> <li>• Fibrogen</li> <li>• Genentech†</li> <li>• Gilead Sciences*</li> <li>• Janssen Pharmaceuticals*</li> <li>• Johnson &amp; Johnson</li> <li>• Medtronic</li> <li>• Merck</li> <li>• Novartis</li> <li>• Orexigen</li> <li>• Pfizer</li> <li>• Regado</li> <li>• The Medicines Company*</li> <li>• Therapeutics</li> <li>• Vida Health†</li> <li>• Vox Media</li> <li>• WebMD*</li> </ul>	None	<ul style="list-style-type: none"> <li>• MyoKardia</li> <li>• Element Science</li> <li>• Scanadu*</li> </ul>	<ul style="list-style-type: none"> <li>• AstraZeneca*</li> <li>• Bristol-Myers Squibb*</li> <li>• CSL Behring*</li> <li>• GlaxoSmithKline*</li> <li>• Merck*</li> <li>• Portola Pharmaceuticals*</li> <li>• Sanofi-aventis*</li> <li>• The Medicines Company*</li> </ul>	<ul style="list-style-type: none"> <li>• American Heart Association†</li> <li>• Duke Clinical Research Institute</li> <li>• Scanadu*</li> </ul>	None
Ana Barac	MedStar Heart and Vascular Institute— Director, Cardio-Oncology Program	<ul style="list-style-type: none"> <li>• Genentech</li> <li>• Cell Therapeutics</li> </ul>	None	None	<ul style="list-style-type: none"> <li>• Genentech*</li> <li>• NIH</li> </ul>	None	None
John E. Brush, Jr.	Sentara Cardiology Specialists—Consulting Cardiologist	None	None	None	None	None	None
Joseph A. Hill	UT Southwestern Medical Center—Professor of Medicine and Molecular Biology	None	None	None	None	None	<ul style="list-style-type: none"> <li>• Defendant, 2012</li> </ul>

Committee Member	Employment	Consultant	Speaker's Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional/ Organizational or Other Financial Benefit	Expert Witness
Harlan Krumholz	Yale University School of Medicine— Harold H. Hines, Jr. Professor of Medicine and Epidemiology and Public Health	<ul style="list-style-type: none"> <li>Institute for Healthcare Improvement</li> <li>Premier*</li> </ul>			<ul style="list-style-type: none"> <li>AHRQ*</li> <li>Catherine and Patrick Weldon Donaghe Medical Research Foundation*</li> <li>FDA*</li> <li>Fuwai Hospital*</li> <li>Johnson &amp; Johnson*</li> <li>Medtronic*</li> <li>National Cancer Institute*</li> <li>NHLBI*</li> <li>Robert Wood Johnson Foundation*</li> <li>The Commonwealth Fund*</li> </ul>	<ul style="list-style-type: none"> <li>American Board of Internal Medicine*</li> <li>American Heart Association*</li> <li>Cardiovascular Outcomes†</li> <li>ImageCOR</li> <li>Massachusetts Medical Society*</li> <li>Patient-Centered Outcomes Research Institute*</li> <li>United Health*</li> <li>Veterans Health Administration*</li> </ul>	
Michael S. Lauer	National Heart, Lung, and Blood Institute —Director, Division of Cardiovascular Sciences	None	None	None	None	None	None
Chittur A. Sivaram	University of Oklahoma Health Sciences Center— Program Director, Cardiovascular Section	<ul style="list-style-type: none"> <li>Medtronic</li> </ul>	None	None	None	None	None
Mark B. Taubman	University of Rochester Medical Center— Charles A. Dewey Professor and Chairman of Medicine	None	None	None	None	None	None
Jeffrey L. Williams	The Good Samaritan Hospital and Lebanon Cardiology Associates— Medical Director, Clinical Cardiac Electrophysiology	None	None	<ul style="list-style-type: none"> <li>Advanced Cardiac Life Sciences</li> </ul>	None	None	<ul style="list-style-type: none"> <li>Defendant, cardiology workforce projections, 2014</li> </ul>

This table represents all healthcare relationships of committee members with industry and other entities by authors, including those not deemed to be relevant, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of  $\geq 5\%$  of the voting stock or share of the business entity, or ownership of  $\geq \$10,000$  of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year.

Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACCF Disclosure Policy for Writing Committees.

\*Significant relationship.

†No financial benefit.

AHRQ = Agency for Healthcare Research and Quality; FDA = Food and Drug Administration; NHLBI = National Heart, Lung, and Blood Institute.